interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Navepegritide

Generic competition · all medicines · read 12 November 2026

Is there a generic of Navepegritide, and who makes it?

Navepegritide appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Navepegritide1 dosage-form group in the Orange Book
0generic makers listed
  1. Navepegritide appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Powder, Subcutaneous

Brand listed, no generic listed as marketed

Brand listed as marketed: Yuviwel. No generic is listed as marketed.

20202025203020352040204501brand 2026data datePatent 8906847 listed to expire 30 April 2031Patent 12239689 listed to expire 5 January 2037Patent 12156917 listed to expire 5 January 2037Patent 10835578 listed to expire 5 January 2037Patent 11154593 listed to expire 5 January 2037Patent 12083182 listed to expire 5 January 2037Patent 11311604 listed to expire 5 January 2037Patent 11389511 listed to expire 5 January 2037Patent 11224661 listed to expire 5 January 2037Patent 11413351 listed to expire 5 January 2037Patent 11389510 listed to expire 5 January 2037Patent 12377133 listed to expire 12 November 2042Exclusivity NCE to 27 February 2031Exclusivity ODE-516 to 27 February 2033
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 27 February 2031Exclusivity NCE Yuviwel
  • 27 February 2033Exclusivity ODE-516 Yuviwel
  • 30 April 2031Patent 8906847 drug substance
  • 5 January 2037Patent 12239689
  • 5 January 2037Patent 12156917
  • 5 January 2037Patent 10835578 drug substance
  • 5 January 2037Patent 11154593 drug substance
  • 5 January 2037Patent 12083182
  • 5 January 2037Patent 11311604 drug substance
  • 5 January 2037Patent 11389511 drug product

4 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.